A clinical-stage pharmaceutical company developing novel therapeutics to treat important diseases such as non-alcoholic steatohepatitis (NASH) and various cancers. Our expertise in FASN enables us to break new ground in targeting dysfunctional metabolic pathways.

body

We’ve created a platform of proprietary, selective FASN inhibitors. Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class FASN inhibitor. TVB-2640 is rapidly absorbed in the human body with well-behaved pharmacokinetics.

Pipeline

FASN Inhibitor

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

NASH

Title

58%

TVB-2640

Oncology

Title

58%

TVB-3567

Undisclosed

Title

22%

FASN Inhibitor – TVB-2640

Indication – NASH

Phase 2

Title

70%

FASN Inhibitor – TVB-2640

Indication – Oncology

Phase 2

Title

70%

FASN Inhibitor – TVB-3567

Indication – Undisclosed

Preclinical

Title

30%

Posters & Publications

09/2020 in Oncology

Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel

European Society for Medical Oncology (ESMO) Congress
Read More
08/2020 in NASH

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress
Read More
08/2020 in NASH

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress
Read More